

Intuitive Surgical Announces \$17.1 Million Third Quarter Revenue -- Up 57% Over Prior Year

October 24, 2002

SUNNYVALE, Calif., Oct 24, 2002 (BUSINESS WIRE) -- Intuitive Surgical, Inc. (Nasdaq:ISRG), the leader in operative surgical robotics, today reported sales of \$17.1 million in the third quarter of 2002, up 57% from \$10.9 million reported in the third quarter of 2001

The sales increase was driven by higher da Vinci(TM) Surgical System placements and continued growth of recurring revenue. Intuitive shipped 14 da Vinci(TM) Surgical Systems during the third quarter of 2002 compared with 10 in the third quarter last year. Intuitive ended the quarter with 132 cumulative da Vinci(TM) Surgical System placements. Third quarter 2002 recurring revenue, consisting of instruments, accessories, and service was \$3.9 million, up 135% from \$1.7 million for the same period last year. Recurring revenue accounted for 23% of total third quarter revenue compared to 15% for the third quarter 2001.

Total third quarter 2002 systems sales were \$13.2 million, instruments and accessories \$2.5 million, and service revenue \$1.4 million. The following table compares third quarter and year-to-date 2002 revenue and da Vinci(TM) Surgical System placements to the prior year.

Third Quarter Year-to-Date 2002 2001 Incr. 2002 2001 Incr.

Revenue (\$ Millions)

da Vinci(TM)Surgical

Systems \$ 13.2 \$ 9.2 \$ 4.0 \$ 40.5 \$ 31.0 \$ 9.5 Instruments/Accys \$ 2.5 \$ 1.1 \$ 1.4 \$ 6.9 \$ 3.4 \$ 3.5

rvice \$ 1.4 \$ 0.6 \$ 0.8 \$ 3.5 \$ 1.3 \$ 2.2

\$ 17.1 \$ 10.9 \$ 6.2 \$ 50.9 \$ 35.7 \$ 15.2

System Population

Placements 14 10 4 43 34 9

Cumulative Placements 132 74 58 132 74 58

Intuitive's gross margin for the third quarter of 2002 was 51%, compared with 47% for the third quarter of 2001. Gross margin improvement resulted largely from increased sales and a higher average da Vinci(TM) Surgical System selling price.

Total operating expenses for the third quarter of 2002 were \$15.6 million, compared to \$10.9 million in the third quarter 2001 and \$14.4 million in the second quarter of this year. The sequential increase resulted primarily from litigation costs incurred in our Delaware trial against Computer Motion and charges taken for unauthorized purchases of administrative supplies, unusable by the company and expensed during the quarter. Intuitive is actively pursuing a refund for the unauthorized purchases and has taken appropriate measures prevent any future recurrence. Apart from the impact of these two non-recurring events, operating expenses were in line with management's expectations.

Net loss for the third quarter of 2002 was \$6.5 million, compared to a net loss of \$4.8 million for the third quarter of 2001. Basic and diluted net loss per share was \$0.18, compared to a net loss per share of \$0.13 for the third quarter of 2001.

Commenting on the announcement, Lonnie Smith, President and CEO of Intuitive Surgical said: "We are pleased with our continued systems and recurring revenue growth. We were able to maintain sales results through the seasonally slower summer period and we look forward to achieving higher sales in the fourth quarter."

The company will also announce these results at a conference call today at 1:30 PM PT. The dial-in numbers for this call are 877-909-3508 for U.S. calls and 484-630-4228 for international calls. The passcode is ISRG and the meeting leader is Mr. Lonnie Smith.

About the da Vinci(TM) Surgical System

The da Vinci(TM) Surgical System consists of a surgeon's viewing and control console having an integrated, high-performance InSite(TM) 3-D vision system, a patient-side cart consisting of three robotic arms that position and precisely maneuver endoscopic instruments and an endoscope, and a variety of articulating EndoWrist(TM) Instruments. By integrating computer-enhanced technology with surgeons' technical skills, Intuitive believes that its System enables surgeons to perform better surgery in a manner never before experienced. The da Vinci(TM) Surgical System seamlessly and directly translates the surgeon's natural hand, wrist and finger movements on instrument controls at the surgeon's console outside the patient's body into corresponding micro-movements of the instrument tips positioned inside the patient through small puncture incisions, or ports.

The statements contained in this release may be deemed to contain "forward-looking statements." Such statements are indicated by words or phrases such as "anticipate," "estimate," "projects," "believes," "intends," "expects" and similar words and phrases. Actual results may differ materially from those expressed or implied in any forward-looking statement as a result of certain risks and uncertainties, including, without limitation, competition and market acceptance of the Company's products, ability to obtain regulatory approvals and third-party reimbursement, ability to raise additional capital and other risks and uncertainties detailed in the Company's Securities and Exchange Commission filings. Prospective investors are cautioned not to place undue reliance on such forward-looking statements.

INTUITIVE SURGICAL, INCORPORATED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (IN THOUSANDS, EXCEPT PER SHARE DATA)

Three months ended

September 30, September 30,

2002 2001

Sales \$ 17,081 \$ 10,861 Cost of sales 8,340 5,750

Gross profit 8,741 5,111

Operating costs and expenses:

Research and development 3,890 3,493

Selling, general and

administrative 11,693 7,452

Total operating costs

 and expenses
 15,583
 10,945

 Loss from operations
 (6,842)
 (5,834)

 Other income/(expense)
 378
 1,036

Net loss \$ (6,464) \$ (4,798)

Weighted average shares outstanding used to compute

net loss per share 36,499 36,056

Loss per share -

basic and diluted \$ (0.18) \$ (0.13)

INTUITIVE SURGICAL, INCORPORATED

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

16,688

(IN THOUSANDS, EXCEPT PER SHARE DATA)

Nine months ended

September 30, September 30,

2002 2001

 Sales
 \$ 50,877
 \$ 35,660

 Cost of sales
 25,072
 18,972

Gross profit 25,805 Operating costs and expenses:

Research and development 12,767 10,060

Selling, general and

Total operating costs

administrative 30,262 21,952

and expenses 43,029 32,012 Loss from operations (17,224) (15,324) Other income/(expense) 1,403 2,876

Net loss (15,821) \$(12,448)

Weighted average shares outstanding used to compute

net loss per share 36,397 35,704

Loss per share -

basic and diluted \$ (0.43) \$ (0.35)

INTUITIVE SURGICAL, INCORPORATED CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS)

(Unaudited)

September 30, December 31,

2002	2001 (a)	
Assets Current assets: Cash, cash equivalents ar short-term investments Accounts receivable, net Inventories, net Prepaid expenses	\$ 48,505 19,044 9,871 2,022	
Total current assets Property and equipment, ne Other assets	79,442 t 10,68	7,834
Total assets \$ 9	92,855 \$	
Liabilities and stockholders Current Liabilities: Accounts payable Accrued compensation an employee benefits Warranty provision Accrued liabilities Deferred revenue Current portion of notes payable	\$ 9,099 dd 4,057 2,479 3,658 4,515	\$ 8,300 2,537 1,831 3,128 3,870 1,631
Total current liabilities Notes payable Stockholders' equity Common stock Additional paid-in capital Deferred compensation Accumulated deficit Accumulated other comprehensive income	1,458	
Total stockholders' equity	65,869	78,293
======	\$ 92,855 === ====	

⁽a) -- Derived from the audited financial statements included in our annual report on form 10K for the fiscal year ended December 31, 2001 but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

CONTACT: Intuitive Surgical Ben Gong, 408/523-2175 Sarah Norton, 408/523-2161